ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1094 • 2015 ACR/ARHP Annual Meeting

    Increased IgA Plasmablasts Are Associated with Rheumatoid Arthritis-Related Autoantibodies in the Absence of Inflammatory Arthritis

    Jennifer Kinslow1, Lisa Blum2, Kevin D. Deane3, Kristen Demoruelle4, Mark C. Parish5, Sarah Kongpachith6, Lauren J. Lahey7, Jill M. Norris8,9, William H. Robinson10 and V. Michael Holers11, 1Rheumatology, University of Colorado, Aurora, CO, 2Stanford University, Palo Alto, CA, 3Division of Rheumatology, U Colo Denver, Aurora, CO, 4Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 5Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, 6Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 7Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 8University of Colorado Denver, Aurora, CO, 9Epidemiology, Colorado School of Public Health, Aurora, CO, 10Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 11Rheumatology Division, Univ of Colorado School of Med, Aurora, CO

    Background/Purpose: Rheumatoid Arthritis (RA) autoimmunity starts years before clinically apparent inflammatory arthritis (IA) develops, and elevated disease-specific autoantibodies, including anti-citrullinated protein antibodies (ACPA) and rheumatoid…
  • Abstract Number: 1095 • 2015 ACR/ARHP Annual Meeting

    Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis

    Marije K. Verheul1, Alvin Yea2, Andrea Seaman2, Robert A. Cordfunke3, Jan W. Drijfhout4, George M. Janssen4, Arnoud de Ru3, Peter A. van Veelen4, René E. M. Toes5, Michael Mahler2 and Leendert A. Trouw1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Inova Diagnostics, San Diego, CA, 3IHB, Leiden University Medical Center, Leiden, Netherlands, 4Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Antibodies targeting carbamylated proteins (anti-CarP) were recently identified in serum samples from patients with rheumatoid arthritis (RA). The presence of anti-CarP antibodies was associated…
  • Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting

    B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis

    Victor Wang1, Nida Meednu1, Wen Sun2, Javier Rangel-Moreno3, Lianping Xing2 and Jennifer H. Anolik1, 1Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 2Pathology & Lab Medicine, University of Rochester Medical Center, Rochester, NY, 3Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…
  • Abstract Number: 1097 • 2015 ACR/ARHP Annual Meeting

    Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis

    Stephen Morris, Alain Laurent, Lori Jerome, Alain Boudreault, Helen Ashdown, Yannick Rose, Patrick Bureau, Shou-Yun Yin, Patrick Cleroux, Delphine Labit, Nicholas Henry, Marie-Noelle Tremblay, Marlyna Guerard, Emilie Dumas Bérubé and Kosta Spathis, Pharmascience Inc., Ville St-Laurent, QC, Canada

    Background/Purpose: Bruton’s tyrosine kinase (BTK) is an important component of B cell and Fc receptor signaling and has been shown to be critical for B-cell…
  • Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting

    Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts

    Georg Pongratz1, Rainer Straub2 and Torsten Lowin3, 1Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, 2Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
  • Abstract Number: 1099 • 2015 ACR/ARHP Annual Meeting

    Single Cell RNA-Seq Analysis of Citrullinated Alpha-Enolase Peptide-Specific B Cells in RA

    Yogita Ghodke-Puranik1, Na Zhang2, Jessica M. Dorschner1, Anna Shmagel3, Zhongbo Jin1, Philip Titcombe4, Timothy B. Niewold1 and Daniel Mueller5, 1Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 2Medicine, University of Minnesota Medical School, Minneapolis, MN, 3Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN, 4University of Minnesota Medical School, Minneapolis, MN, 5Medicine/Rheumatic & Autoimmune Diseases, University of Minnesota Medical School, Minneapolis, MN

    Background/Purpose: The high prevalence of citrullinated protein antibodies and improvement following rituximab anti-CD20 therapy both suggest that B cells are important in the pathogenesis of…
  • Abstract Number: 1100 • 2015 ACR/ARHP Annual Meeting

    Citrullinated Antigen-Specific B Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis: Identification and Phenotypic Characterization

    Priscilla Kerkman1, Ellen I.H. van der Voort1, Arnaud Zaldumbide2, Emeline Fabre1, Yoann Rombouts1, Theo Rispens3, Gertjan Wolbink4, Rob Hoeben2, Hergen Spits5, Dominique Baeten6, T. W. J. Huizinga1, René E. M. Toes1 and Hans Ulrich Scherer1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands, 3Sanquin Research, Amsterdam, Netherlands, 4Immunopathology, Sanquin Research, Amsterdam, Netherlands, 5Department of Cell Biology and Histology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 6Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of anti-citrullinated protein antibodies (ACPA) in the majority of patients. ACPA represent highly disease-specific biomarkers that…
  • Abstract Number: 1101 • 2015 ACR/ARHP Annual Meeting

    Matrix Metalloproteinase-10 (Stromelysin 2) Is a Target of Robust Autoimmune T and B Cell Responses in Antibiotic-Refractory Lyme Arthritis, but Not in Rheumatoid Arthritis

    Jameson T. Crowley1, Elise E. Drouin2, Annalisa Pianta1, Klemen Strle1, Qi Wang3, Catherine E. Costello3 and Allen C. Steere4, 1Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Medicine, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, 4Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Infection-induced autoimmunity has been hypothesized to have a pathogenic role in antibiotic-refractory Lyme arthritis (LA). We previously identified 3 autoantigens, endothelial cell growth factor,…
  • Abstract Number: 1102 • 2015 ACR/ARHP Annual Meeting

    CD19+CD24-CD38hi B-Cell Subset: A Potential Biomarker for IgG4-Related Disease

    Wen Zhang1,2, Wei Lin3, Yu Chen4, Yunjiao Yang4, Hua Chen4, QingJun Wu4, Yunyun Fei4, Chaojun Hu4, Yongzhe Li3, Xuan Zhang3, Yan Zhao4, Fengchun Zhang3, Xiaofeng Zeng4 and Peter E. Lipsky5, 1Rheuamtology, Peking Union Medical College Hospital, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, 3Peking Union Medical College Hospital, Beijing, China, 4Rheumatology, Peking Union Medical College Hospital, Beijing, China, 5Bldg 10 Rm 6d47c, National Institutes of Health, Bethesda, MD

    Background/Purpose: To investigate a B-cell subpopulation, exhibiting CD19+CD24-CD38hi phenotype, can be a biomarker for diagnosis and disease activity in IgG4 related disease (IgG4-RD). Methods: Circulating…
  • Abstract Number: 1103 • 2015 ACR/ARHP Annual Meeting

    Phosphatidylserine Outer Layer Translocation Is Implicated in IL-10 Secretion By Human Regulatory B Cells

    Charlotte Hua1, Rachel Audo2, Michael Hahne2, Bernard Combe3, Jacques Morel3 and Claire I. Daien3, 1Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 2IGMM-CNRS UMR5535, Montpellier, France, 3Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France

    Background/Purpose: B cells can have a negative regulatory role, mainly mediated by interleukin 10 (IL-10) and we recently showed that IL-10 producing B cells (B10…
  • Abstract Number: 1104 • 2015 ACR/ARHP Annual Meeting

    Mouse B Cells Require Glucose and Free Fatty Acids As Carbon Sources for Cytokine and Chemokine Secretion

    Doujiao Wu1, Dongyue Huang2, Edward Pearce1 and Alfred Kim2, 1Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, 2Rheumatology, Washington University School of Medicine, Saint Louis, MO

    Background/Purpose: B cells contribute to disease pathophysiology through several mechanisms, including cytokine and chemokine secretion. A wide variety of stimuli can activate B cells including…
  • Abstract Number: 1105 • 2015 ACR/ARHP Annual Meeting

    The IgG/IgG4 mRNA Ratio By Quantitative PCR Accurately Diagnoses IgG4-Related Disease and Predicts Treatment Response

    Lowiek Hubers1, Marieke Doorenspleet2, Paulus Klarenbeek3, Emma Culver4, Lucas Maillette de Buy Wenniger5, Roger Chapman4, Stan Van de Graaf6, Joanne Verheij7, Thomas Van Gulik8, Frank Baas9, Ellie Barnes4, Ulrich Beuers1 and Niek De Vries3, 1Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 4Translational Gastroenterology Unit and NDM Oxford University, Translational Gastroenterology Unit and NDM Oxford University, John Radcliffe Hospital/Oxford University, Oxford, United Kingdom, 51Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research,, Dept. of Gastroenterology & Hepatology and Tytgat Institute of Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 7Dept. of Pathology, Dept. of Pathology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 8Dept. of Surgery, Dept. of Surgery, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 9Dept. of Genome Analysis, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose : IgG4-associated cholangitis (IAC) and autoimmune pancreatitis (AIP) are major manifestations of IgG4-related disease (IRD). Misdiagnosis and inadequate treatment are common since IAC and…
  • Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

    Christian Goess1, Candace Graff2, Ting Ting Zhang2, Gregory Preston2, Richard McCarthy1, Matthew Perham1, Jacqueline Loud1, Christopher M. Harris1, Sara Murdock1, Erik Sampson3, Michael Hoemann4, Michael Friedman4, Robert Talanian3, Jeremy Edmunds4 and Andrew Long1, 1Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
  • Abstract Number: 1107 • 2015 ACR/ARHP Annual Meeting

    Inhibition of B Cell Activation and Plasma Cell Differentiation By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22

    Natalia V. Giltiay1, Geraldine L. Shu2, Anthony Shock3 and Edward A. Clark1,2, 1Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, 2Department of Immunology, University of Washington, Seattle, WA, 3UCB Pharma, Slough, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by B cell hyperactivity and production of autoantibodies. Treatment of patients with moderate-to-severe SLE with epratuzumab, a humanized…
  • Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting

    Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor

    Simon Lumb1, Sarah J. Fleischer2, Capucine Daridon2, Alison Maloney1, Anthony Shock1 and Thomas Dorner2, 1UCB Pharma, Slough, United Kingdom, 2Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany

    Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…
  • « Previous Page
  • 1
  • …
  • 1942
  • 1943
  • 1944
  • 1945
  • 1946
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology